Cyclin D3 gene amplification in bladder carcinoma in situ.
Carcinoma in situ (CIS) is a non-papillary high-grade, potentially aggressive, and unpredictable manifestation of bladder urothelial carcinoma. The aim of this study was to assess patterns of Cyclin D3 gene amplification in Bacillus Calmette-Guerin (BCG)-treated CIS and correlate gene status with recurrence-free and progression-free survival. A sequential cohort series of 28 primary (isolated) or secondary (concomitant) bladder CIS samples in which there was enough tissue material to assess Cyclin D3 gene status by fluorescent in situ hybridization was the study group. Cyclin D3 gene amplification was present in 29% of secondary CIS; none of primary CIS samples had Cyclin D3 gene amplification. Cyclin D3 amplification was related to recurrence- (p = 0.046) and progression-free survival (p = 0.002). Type of bladder CIS (primary vs. secondary) was unrelated to recurrence- or progression-free survival in the current series. Cox's regression analysis selected Cyclin D3 as an independent predictor of progression-free survival (p = 0.041, relative risk = 61.503, 95% confidence interval = 1.1-274.710). None of primary CIS cases recurred on follow-up; nine secondary CIS recurred and four of them progressed to invasive bladder carcinoma HG T1 (n = 1), T2b N0M0 (n = 1), T3b N1M0 (n = 1) and T4aN1M1 (n = 1). Mean recurrence ± SD (months) occurred at 19.5 ± 2.06 (95% (confidence interval (CI)), 15.5-23.6); mean progression (months) occurred at 23.8 ± 1.46 (95% (CI), 20.9-26.7). Our study suggests that Cyclin D3 gene amplification might be a predictor of aggressiveness in BCG-treated CIS.
Lopez-Beltran
Antonio
A
Department of Pathology, Cordoba University Medical School, Spain. em1lobea@uco.es
Ordóñez
Jose L
JL
Otero
Ana P
AP
Blanca
Ana
A
Sevillano
Vicky
V
Sanchez-Carbayo
Marta
M
Muñoz
Elisa
E
Cheng
Liang
L
Montironi
Rodolfo
R
de Alava
Enrique
E
D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics*; D015153:Blotting, Western; D002278:Carcinoma in Situ / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D056743:Cyclin D3 / Q000235:genetics*; D018572:Disease-Free Survival; D005260:Female; D005784:Gene Amplification; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000235:genetics / Q000401:mortality; D016016:Proportional Hazards Models; D046888:Tissue Array Analysis; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality
D001500:BCG Vaccine; D014408:Biomarkers, Tumor; C534696:CCND3 protein, human; D056743:Cyclin D3
Cancer Res. 2004 Jun 1;64(11):4040-8
15173019
Urol Oncol. 2009 May-Jun;27(3):258-62
18440839
J Urol. 2001 May;165(5):1488-91
11342902
Anticancer Res. 2008 Sep-Oct;28(5B):2893-900
19031931
Eur Urol. 2006 Jul;50(1):76-82
16413663
Int J Cancer. 1996 Jan 26;65(3):323-7
8575852
Scand J Urol Nephrol. 2004;38(4):285-90
15669587
Urology. 2005 Dec;66(6 Suppl 1):90-107
16399418
Eur Urol. 2004 May;45(5):593-9
15082201
J Pathol. 2006 May;209(1):106-13
16482499
Urology. 2001 Jan;57(1):60-5
11164145
J Natl Compr Canc Netw. 2009 Jan;7(1):48-57
19176205
Cancer Lett. 2007 Jun 8;250(2):292-9
17126995
Eur Urol. 2004 May;45(5):606-12
15082203
Eur Urol. 2005 Sep;48(3):363-71
15994003
Eur Urol. 2010 Jan;57(1):12-20
19762144
Scand J Urol Nephrol Suppl. 2008 Sep;(218):95-109
18815924
Cancer. 1999 Jun 1;85(11):2469-74
10357420
Clin Cancer Res. 2005 Jan 1;11(1):242-8
15671552
Eur Urol. 2007 Jan;51(1):152-60
17011114
Scand J Urol Nephrol Suppl. 1994;157:147-51
7939446
Cancer Res. 2002 Feb 1;62(3):809-18
11830537
Eur Urol. 2004 Feb;45(2):142-6
14733997
Am J Pathol. 2002 Oct;161(4):1119-25
12368185
J Urol. 1999 Mar;161(3):792-8
10022686
Int J Cancer. 2009 Nov 1;125(9):2095-103
19637316
Urology. 2003 Jun;61(6):1140-5
12809883